Baranyi Andreas, Enko Dietmar, Meinitzer Andreas, Von Lewinski Dirk, Rothenhäusler Hans-Bernd, Harpf Leonhard, Traninger Heimo, Obermayer-Pietsch Barbara, Harb Birgit M, Schweinzer Melanie, Platzer Moritz, Zelzer Sieglinde
Division of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, 8036 Graz, Austria.
Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, 8036 Graz, Austria.
Antioxidants (Basel). 2022 Oct 22;11(11):2083. doi: 10.3390/antiox11112083.
While myeloperoxidase (MPO) serves as an indicator of both neutrophil and innate-immune-system function, the potential suppression of the innate immune system in patients with acute myocardial infarction (AMI)-induced depression might be evidenced by a decrease in MPO serum levels. The aim of this prospective study was to (1) determine whether serum concentrations of MPO vary immediately and 6 months after AMI and (2) to investigate whether MPO concentrations at the time of the AMI are significant predictors of AMI-induced depression and the depression-associated suppression of the innate immune system. A total of 109 AMI patients were assessed with the Hamilton Depression Scale (HAMD-17) immediately after admission to the hospital and 6 months later. The MPO status was assessed with serum samples, which were also collected immediately and 6 months after AMI. The depressive patients showed significantly lower MPO blood levels immediately and 6 months after the AMI compared to the patients without depression (ANCOVA: MPO (depression) F = 4.764, df = 1, = 0.031). The baseline MPO was observed as a significant predictor ( = 0.027) of AMI-induced depression 6 months after AMI. MPO is a potential biomarker for AMI-induced depression, indicating a depression-associated suppression of the innate immune system.
虽然髓过氧化物酶（MPO）是中性粒细胞和先天免疫系统功能的指标，但急性心肌梗死（AMI）所致抑郁症患者的先天免疫系统可能受到抑制，这可通过MPO血清水平降低得到证实。这项前瞻性研究的目的是：（1）确定AMI后即刻及6个月时MPO的血清浓度是否发生变化；（2）研究AMI时的MPO浓度是否是AMI所致抑郁症及抑郁症相关的先天免疫系统抑制的重要预测指标。共有109例AMI患者在入院后即刻及6个月后接受汉密尔顿抑郁量表（HAMD-17）评估。MPO状态通过血清样本进行评估，这些样本也在AMI后即刻及6个月时采集。与无抑郁症的患者相比，抑郁症患者在AMI后即刻及6个月时的MPO血液水平显著降低（协方差分析：MPO（抑郁症）F = 4.764，自由度 = 1，P = 0.031）。观察到基线MPO是AMI后6个月时AMI所致抑郁症的重要预测指标（P = 0.027）。MPO是AMI所致抑郁症的潜在生物标志物，表明抑郁症相关的先天免疫系统受到抑制。
